Angelina Jolie and the One Percent
By Gayle Sulik,
Scientific American
| 05. 20. 2013
After learning that she had inherited a mutation on one of the so-called breast cancer genes, actress Angelina Jolie decided to have a double mastectomy to reduce her risk of developing breast cancer. She also plans to have her ovaries removed to reduce her risk of ovarian cancer. It may sound like a drastic measure, but mutations on the breast cancer genes (BRCA1 and BRCA2) increase the overall risk of developing several cancers, including prostate, pancreatic, testicular, ovarian, and breast. On average, a woman with a BRCA1 mutation (the one Jolie has) has a 65 percent risk of developing breast cancer and a 39 percent risk of ovarian cancer by the age of 70. Jolie’s mother died of ovarian cancer at age 56, after ten years of living with the disease. Jolie explained her medical decision in an
op-ed in
The New York Times, saying that she decided to be proactive and to minimize the risk as much [she] could.
Since the Angelina Jolie story broke, there’s been a flurry of discussion about risks, medical interventions, access to medical...
Related Articles
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Emma McDonald Kennedy
| 07.11.2024
Louise Perry’s recent article in The Spectator cautions against “The quiet return of eugenics,” a threat she locates in preimplantation genetic testing for polygenic disorders. The technology is billed as a way for parents undergoing IVF to select which embryo to implant based on information about each embryo’s genetic risk factors and traits. These reports, she says, give parents “a very full picture of the adult that embryo could become”––from their child’s risk of developing different diseases to their “likely...